nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—acquired immunodeficiency syndrome	0.286	1	CbGaD
Gliclazide—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0318	0.0644	CbGbCtD
Gliclazide—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0316	0.064	CbGbCtD
Gliclazide—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0303	0.0613	CbGbCtD
Gliclazide—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0299	0.0605	CbGbCtD
Gliclazide—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.027	0.0547	CbGbCtD
Gliclazide—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.027	0.0547	CbGbCtD
Gliclazide—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0264	0.0535	CbGbCtD
Gliclazide—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0248	0.0503	CbGbCtD
Gliclazide—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0248	0.0503	CbGbCtD
Gliclazide—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0233	0.0472	CbGbCtD
Gliclazide—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0226	0.0459	CbGbCtD
Gliclazide—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0225	0.0455	CbGbCtD
Gliclazide—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0225	0.0455	CbGbCtD
Gliclazide—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0205	0.0415	CbGbCtD
Gliclazide—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0205	0.0415	CbGbCtD
Gliclazide—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0196	0.0398	CbGbCtD
Gliclazide—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0194	0.0393	CbGbCtD
Gliclazide—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0188	0.0381	CbGbCtD
Gliclazide—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.017	0.0345	CbGbCtD
Gliclazide—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.017	0.0345	CbGbCtD
Gliclazide—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0163	0.0331	CbGbCtD
Gliclazide—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.001	0.0742	CbGeAlD
Gliclazide—VEGFA—bone marrow—acquired immunodeficiency syndrome	0.000936	0.0692	CbGeAlD
Gliclazide—VEGFA—spinal cord—acquired immunodeficiency syndrome	0.000932	0.069	CbGeAlD
Gliclazide—VEGFA—vagina—acquired immunodeficiency syndrome	0.000896	0.0663	CbGeAlD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000866	0.112	CbGpPWpGaD
Gliclazide—VEGFA—lung—acquired immunodeficiency syndrome	0.000848	0.0627	CbGeAlD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000839	0.109	CbGpPWpGaD
Gliclazide—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000778	0.0575	CbGeAlD
Gliclazide—KCNJ11—lymphoid tissue—acquired immunodeficiency syndrome	0.000735	0.0544	CbGeAlD
Gliclazide—ABCC8—spinal cord—acquired immunodeficiency syndrome	0.000614	0.0454	CbGeAlD
Gliclazide—VEGFA—brain—acquired immunodeficiency syndrome	0.0006	0.0444	CbGeAlD
Gliclazide—VEGFA—lymph node—acquired immunodeficiency syndrome	0.00058	0.0429	CbGeAlD
Gliclazide—KCNJ11—nervous system—acquired immunodeficiency syndrome	0.000562	0.0416	CbGeAlD
Gliclazide—KCNJ11—central nervous system—acquired immunodeficiency syndrome	0.000541	0.04	CbGeAlD
Gliclazide—ABCC8—nervous system—acquired immunodeficiency syndrome	0.000517	0.0383	CbGeAlD
Gliclazide—ABCC8—central nervous system—acquired immunodeficiency syndrome	0.000498	0.0369	CbGeAlD
Gliclazide—VEGFA—S1P3 pathway—CXCR4—acquired immunodeficiency syndrome	0.000444	0.0576	CbGpPWpGaD
Gliclazide—KCNJ11—brain—acquired immunodeficiency syndrome	0.000429	0.0318	CbGeAlD
Gliclazide—KCNJ11—lymph node—acquired immunodeficiency syndrome	0.000415	0.0307	CbGeAlD
Gliclazide—ABCC8—brain—acquired immunodeficiency syndrome	0.000395	0.0293	CbGeAlD
Gliclazide—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000386	0.0285	CbGeAlD
Gliclazide—CYP2C19—blood—acquired immunodeficiency syndrome	0.000367	0.0272	CbGeAlD
Gliclazide—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000341	0.0252	CbGeAlD
Gliclazide—VEGFA—Alpha9 beta1 integrin signaling events—CSF2—acquired immunodeficiency syndrome	0.000333	0.0431	CbGpPWpGaD
Gliclazide—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000299	0.0221	CbGeAlD
Gliclazide—CYP2C9—blood—acquired immunodeficiency syndrome	0.000285	0.0211	CbGeAlD
Gliclazide—ALB—brain—acquired immunodeficiency syndrome	0.000283	0.021	CbGeAlD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000279	0.0362	CbGpPWpGaD
Gliclazide—ALB—lymph node—acquired immunodeficiency syndrome	0.000274	0.0202	CbGeAlD
Gliclazide—VEGFA—EPH-Ephrin signaling—ACTG1—acquired immunodeficiency syndrome	0.000254	0.0329	CbGpPWpGaD
Gliclazide—VEGFA—Hypertrophy Model—IFNG—acquired immunodeficiency syndrome	0.000237	0.0307	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000236	0.0306	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.000204	0.0265	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.000204	0.0265	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.000177	0.0229	CbGpPWpGaD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—ALB—acquired immunodeficiency syndrome	0.000151	0.0196	CbGpPWpGaD
Gliclazide—KCNJ11—Type II diabetes mellitus—TNF—acquired immunodeficiency syndrome	0.000151	0.0195	CbGpPWpGaD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—ALB—acquired immunodeficiency syndrome	0.000146	0.019	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—ACTG1—acquired immunodeficiency syndrome	0.000145	0.0188	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.000134	0.0174	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.000134	0.0174	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.00013	0.0169	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.000127	0.0165	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IFNG—acquired immunodeficiency syndrome	0.000101	0.0131	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—ACTG1—acquired immunodeficiency syndrome	9.44e-05	0.0122	CbGpPWpGaD
Gliclazide—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	9.05e-05	0.000455	CcSEcCtD
Gliclazide—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	9.04e-05	0.000455	CcSEcCtD
Gliclazide—Tremor—Lamivudine—acquired immunodeficiency syndrome	9.03e-05	0.000455	CcSEcCtD
Gliclazide—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	9.02e-05	0.000454	CcSEcCtD
Gliclazide—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	9.01e-05	0.000454	CcSEcCtD
Gliclazide—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	9e-05	0.000453	CcSEcCtD
Gliclazide—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	9e-05	0.000453	CcSEcCtD
Gliclazide—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	8.99e-05	0.000452	CcSEcCtD
Gliclazide—Pruritus—Stavudine—acquired immunodeficiency syndrome	8.97e-05	0.000451	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—IL2—acquired immunodeficiency syndrome	8.97e-05	0.0116	CbGpPWpGaD
Gliclazide—Asthenia—Abacavir—acquired immunodeficiency syndrome	8.96e-05	0.000451	CcSEcCtD
Gliclazide—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	8.96e-05	0.000451	CcSEcCtD
Gliclazide—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	8.95e-05	0.00045	CcSEcCtD
Gliclazide—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	8.94e-05	0.00045	CcSEcCtD
Gliclazide—Chest pain—Ritonavir—acquired immunodeficiency syndrome	8.94e-05	0.00045	CcSEcCtD
Gliclazide—Myalgia—Ritonavir—acquired immunodeficiency syndrome	8.94e-05	0.00045	CcSEcCtD
Gliclazide—Anaemia—Lamivudine—acquired immunodeficiency syndrome	8.91e-05	0.000448	CcSEcCtD
Gliclazide—Anxiety—Ritonavir—acquired immunodeficiency syndrome	8.91e-05	0.000448	CcSEcCtD
Gliclazide—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	8.88e-05	0.000447	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	8.88e-05	0.000447	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	8.85e-05	0.000445	CcSEcCtD
Gliclazide—Pruritus—Abacavir—acquired immunodeficiency syndrome	8.84e-05	0.000445	CcSEcCtD
Gliclazide—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.84e-05	0.000445	CcSEcCtD
Gliclazide—Discomfort—Ritonavir—acquired immunodeficiency syndrome	8.83e-05	0.000444	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.82e-05	0.000444	CcSEcCtD
Gliclazide—Cough—Saquinavir—acquired immunodeficiency syndrome	8.82e-05	0.000444	CcSEcCtD
Gliclazide—Angioedema—Lamivudine—acquired immunodeficiency syndrome	8.81e-05	0.000443	CcSEcCtD
Gliclazide—Pain—Indinavir—acquired immunodeficiency syndrome	8.77e-05	0.000441	CcSEcCtD
Gliclazide—Constipation—Indinavir—acquired immunodeficiency syndrome	8.77e-05	0.000441	CcSEcCtD
Gliclazide—Insomnia—Efavirenz—acquired immunodeficiency syndrome	8.76e-05	0.000441	CcSEcCtD
Gliclazide—Urticaria—Zidovudine—acquired immunodeficiency syndrome	8.76e-05	0.000441	CcSEcCtD
Gliclazide—Convulsion—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000441	CcSEcCtD
Gliclazide—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	8.74e-05	0.00044	CcSEcCtD
Gliclazide—Hypertension—Saquinavir—acquired immunodeficiency syndrome	8.73e-05	0.000439	CcSEcCtD
Gliclazide—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.71e-05	0.000438	CcSEcCtD
Gliclazide—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	8.71e-05	0.000438	CcSEcCtD
Gliclazide—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.7e-05	0.000438	CcSEcCtD
Gliclazide—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	8.7e-05	0.000438	CcSEcCtD
Gliclazide—Malaise—Lamivudine—acquired immunodeficiency syndrome	8.69e-05	0.000437	CcSEcCtD
Gliclazide—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.68e-05	0.000437	CcSEcCtD
Gliclazide—Nausea—Didanosine—acquired immunodeficiency syndrome	8.68e-05	0.000437	CcSEcCtD
Gliclazide—Hypotension—Delavirdine—acquired immunodeficiency syndrome	8.66e-05	0.000436	CcSEcCtD
Gliclazide—Confusional state—Ritonavir—acquired immunodeficiency syndrome	8.64e-05	0.000435	CcSEcCtD
Gliclazide—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	8.63e-05	0.000434	CcSEcCtD
Gliclazide—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	8.63e-05	0.000434	CcSEcCtD
Gliclazide—Somnolence—Efavirenz—acquired immunodeficiency syndrome	8.61e-05	0.000433	CcSEcCtD
Gliclazide—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.6e-05	0.000433	CcSEcCtD
Gliclazide—Chest pain—Saquinavir—acquired immunodeficiency syndrome	8.6e-05	0.000433	CcSEcCtD
Gliclazide—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.6e-05	0.000433	CcSEcCtD
Gliclazide—Anxiety—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000431	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—ALB—acquired immunodeficiency syndrome	8.55e-05	0.0111	CbGpPWpGaD
Gliclazide—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.55e-05	0.00043	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.54e-05	0.00043	CcSEcCtD
Gliclazide—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	8.53e-05	0.000429	CcSEcCtD
Gliclazide—Discomfort—Saquinavir—acquired immunodeficiency syndrome	8.5e-05	0.000428	CcSEcCtD
Gliclazide—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	8.47e-05	0.000426	CcSEcCtD
Gliclazide—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	8.45e-05	0.000425	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	8.44e-05	0.000425	CcSEcCtD
Gliclazide—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.41e-05	0.000423	CcSEcCtD
Gliclazide—Cough—Lamivudine—acquired immunodeficiency syndrome	8.41e-05	0.000423	CcSEcCtD
Gliclazide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.41e-05	0.000423	CcSEcCtD
Gliclazide—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.4e-05	0.000423	CcSEcCtD
Gliclazide—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.39e-05	0.000422	CcSEcCtD
Gliclazide—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.39e-05	0.000422	CcSEcCtD
Gliclazide—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	8.38e-05	0.000422	CcSEcCtD
Gliclazide—Insomnia—Delavirdine—acquired immunodeficiency syndrome	8.38e-05	0.000422	CcSEcCtD
Gliclazide—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	8.36e-05	0.000421	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.36e-05	0.000421	CcSEcCtD
Gliclazide—Convulsion—Lamivudine—acquired immunodeficiency syndrome	8.35e-05	0.00042	CcSEcCtD
Gliclazide—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.35e-05	0.00042	CcSEcCtD
Gliclazide—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.35e-05	0.00042	CcSEcCtD
Gliclazide—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.32e-05	0.000419	CcSEcCtD
Gliclazide—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	8.32e-05	0.000419	CcSEcCtD
Gliclazide—Confusional state—Saquinavir—acquired immunodeficiency syndrome	8.32e-05	0.000418	CcSEcCtD
Gliclazide—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	8.28e-05	0.000417	CcSEcCtD
Gliclazide—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.28e-05	0.000417	CcSEcCtD
Gliclazide—Pain—Efavirenz—acquired immunodeficiency syndrome	8.28e-05	0.000417	CcSEcCtD
Gliclazide—Rash—Nevirapine—acquired immunodeficiency syndrome	8.28e-05	0.000417	CcSEcCtD
Gliclazide—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.27e-05	0.000416	CcSEcCtD
Gliclazide—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	8.26e-05	0.000416	CcSEcCtD
Gliclazide—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.26e-05	0.000416	CcSEcCtD
Gliclazide—Somnolence—Delavirdine—acquired immunodeficiency syndrome	8.24e-05	0.000415	CcSEcCtD
Gliclazide—Headache—Nevirapine—acquired immunodeficiency syndrome	8.23e-05	0.000414	CcSEcCtD
Gliclazide—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	8.21e-05	0.000413	CcSEcCtD
Gliclazide—Chest pain—Lamivudine—acquired immunodeficiency syndrome	8.21e-05	0.000413	CcSEcCtD
Gliclazide—Myalgia—Lamivudine—acquired immunodeficiency syndrome	8.21e-05	0.000413	CcSEcCtD
Gliclazide—Infection—Saquinavir—acquired immunodeficiency syndrome	8.19e-05	0.000412	CcSEcCtD
Gliclazide—Anxiety—Lamivudine—acquired immunodeficiency syndrome	8.18e-05	0.000412	CcSEcCtD
Gliclazide—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	8.16e-05	0.00041	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	8.15e-05	0.00041	CcSEcCtD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—ALB—acquired immunodeficiency syndrome	8.14e-05	0.0106	CbGpPWpGaD
Gliclazide—Urticaria—Indinavir—acquired immunodeficiency syndrome	8.14e-05	0.00041	CcSEcCtD
Gliclazide—Discomfort—Lamivudine—acquired immunodeficiency syndrome	8.11e-05	0.000408	CcSEcCtD
Gliclazide—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.1e-05	0.000408	CcSEcCtD
Gliclazide—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.1e-05	0.000408	CcSEcCtD
Gliclazide—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.09e-05	0.000407	CcSEcCtD
Gliclazide—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.09e-05	0.000407	CcSEcCtD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—IL6—acquired immunodeficiency syndrome	8.08e-05	0.0105	CbGpPWpGaD
Gliclazide—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.08e-05	0.000406	CcSEcCtD
Gliclazide—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.06e-05	0.000406	CcSEcCtD
Gliclazide—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8.03e-05	0.000404	CcSEcCtD
Gliclazide—Rash—Nelfinavir—acquired immunodeficiency syndrome	8.02e-05	0.000404	CcSEcCtD
Gliclazide—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	8.01e-05	0.000403	CcSEcCtD
Gliclazide—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	8.01e-05	0.000403	CcSEcCtD
Gliclazide—Hypotension—Ritonavir—acquired immunodeficiency syndrome	8.01e-05	0.000403	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	8e-05	0.000403	CcSEcCtD
Gliclazide—Rash—Stavudine—acquired immunodeficiency syndrome	8e-05	0.000402	CcSEcCtD
Gliclazide—Fatigue—Delavirdine—acquired immunodeficiency syndrome	7.99e-05	0.000402	CcSEcCtD
Gliclazide—Dermatitis—Stavudine—acquired immunodeficiency syndrome	7.99e-05	0.000402	CcSEcCtD
Gliclazide—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	7.98e-05	0.000402	CcSEcCtD
Gliclazide—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	7.97e-05	0.000401	CcSEcCtD
Gliclazide—Headache—Nelfinavir—acquired immunodeficiency syndrome	7.97e-05	0.000401	CcSEcCtD
Gliclazide—Headache—Stavudine—acquired immunodeficiency syndrome	7.94e-05	0.0004	CcSEcCtD
Gliclazide—Vomiting—Abacavir—acquired immunodeficiency syndrome	7.94e-05	0.0004	CcSEcCtD
Gliclazide—Confusional state—Lamivudine—acquired immunodeficiency syndrome	7.93e-05	0.000399	CcSEcCtD
Gliclazide—Constipation—Delavirdine—acquired immunodeficiency syndrome	7.92e-05	0.000399	CcSEcCtD
Gliclazide—Pain—Delavirdine—acquired immunodeficiency syndrome	7.92e-05	0.000399	CcSEcCtD
Gliclazide—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	7.92e-05	0.000399	CcSEcCtD
Gliclazide—Asthenia—Zidovudine—acquired immunodeficiency syndrome	7.91e-05	0.000398	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	7.88e-05	0.0102	CbGpPWpGaD
Gliclazide—Rash—Abacavir—acquired immunodeficiency syndrome	7.88e-05	0.000396	CcSEcCtD
Gliclazide—Dermatitis—Abacavir—acquired immunodeficiency syndrome	7.87e-05	0.000396	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	7.86e-05	0.0102	CbGpPWpGaD
Gliclazide—Headache—Abacavir—acquired immunodeficiency syndrome	7.83e-05	0.000394	CcSEcCtD
Gliclazide—Infection—Lamivudine—acquired immunodeficiency syndrome	7.82e-05	0.000393	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.81e-05	0.000393	CcSEcCtD
Gliclazide—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.8e-05	0.000393	CcSEcCtD
Gliclazide—Pruritus—Zidovudine—acquired immunodeficiency syndrome	7.8e-05	0.000392	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	7.78e-05	0.0101	CbGpPWpGaD
Gliclazide—Insomnia—Ritonavir—acquired immunodeficiency syndrome	7.75e-05	0.00039	CcSEcCtD
Gliclazide—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.72e-05	0.000388	CcSEcCtD
Gliclazide—Hypotension—Saquinavir—acquired immunodeficiency syndrome	7.71e-05	0.000388	CcSEcCtD
Gliclazide—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	7.7e-05	0.000388	CcSEcCtD
Gliclazide—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	7.7e-05	0.000387	CcSEcCtD
Gliclazide—Urticaria—Efavirenz—acquired immunodeficiency syndrome	7.69e-05	0.000387	CcSEcCtD
Gliclazide—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	7.66e-05	0.000385	CcSEcCtD
Gliclazide—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.66e-05	0.000385	CcSEcCtD
Gliclazide—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.64e-05	0.000385	CcSEcCtD
Gliclazide—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.64e-05	0.000384	CcSEcCtD
Gliclazide—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	7.64e-05	0.000384	CcSEcCtD
Gliclazide—Somnolence—Ritonavir—acquired immunodeficiency syndrome	7.62e-05	0.000383	CcSEcCtD
Gliclazide—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	7.61e-05	0.000383	CcSEcCtD
Gliclazide—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.58e-05	0.000381	CcSEcCtD
Gliclazide—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.56e-05	0.00038	CcSEcCtD
Gliclazide—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	7.55e-05	0.00038	CcSEcCtD
Gliclazide—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	7.54e-05	0.00038	CcSEcCtD
Gliclazide—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.54e-05	0.000379	CcSEcCtD
Gliclazide—Nausea—Stavudine—acquired immunodeficiency syndrome	7.53e-05	0.000379	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.51e-05	0.000378	CcSEcCtD
Gliclazide—Insomnia—Saquinavir—acquired immunodeficiency syndrome	7.46e-05	0.000375	CcSEcCtD
Gliclazide—Nausea—Abacavir—acquired immunodeficiency syndrome	7.42e-05	0.000373	CcSEcCtD
Gliclazide—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	7.41e-05	0.000373	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.4e-05	0.000372	CcSEcCtD
Gliclazide—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.39e-05	0.000372	CcSEcCtD
Gliclazide—Urticaria—Delavirdine—acquired immunodeficiency syndrome	7.36e-05	0.00037	CcSEcCtD
Gliclazide—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.35e-05	0.00037	CcSEcCtD
Gliclazide—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	7.35e-05	0.00037	CcSEcCtD
Gliclazide—Hypotension—Lamivudine—acquired immunodeficiency syndrome	7.35e-05	0.00037	CcSEcCtD
Gliclazide—Somnolence—Saquinavir—acquired immunodeficiency syndrome	7.33e-05	0.000369	CcSEcCtD
Gliclazide—Pain—Ritonavir—acquired immunodeficiency syndrome	7.33e-05	0.000369	CcSEcCtD
Gliclazide—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.33e-05	0.000369	CcSEcCtD
Gliclazide—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	7.33e-05	0.000369	CcSEcCtD
Gliclazide—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.33e-05	0.000369	CcSEcCtD
Gliclazide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.29e-05	0.000367	CcSEcCtD
Gliclazide—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	7.26e-05	0.000365	CcSEcCtD
Gliclazide—Pruritus—Indinavir—acquired immunodeficiency syndrome	7.25e-05	0.000365	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.17e-05	0.000361	CcSEcCtD
Gliclazide—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.14e-05	0.000359	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.12e-05	0.000358	CcSEcCtD
Gliclazide—Insomnia—Lamivudine—acquired immunodeficiency syndrome	7.12e-05	0.000358	CcSEcCtD
Gliclazide—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.11e-05	0.000358	CcSEcCtD
Gliclazide—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	7.07e-05	0.000356	CcSEcCtD
Gliclazide—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	7.06e-05	0.000355	CcSEcCtD
Gliclazide—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.000355	CcSEcCtD
Gliclazide—Pain—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.000355	CcSEcCtD
Gliclazide—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	7.02e-05	0.000353	CcSEcCtD
Gliclazide—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	7.01e-05	0.000353	CcSEcCtD
Gliclazide—Vomiting—Zidovudine—acquired immunodeficiency syndrome	7.01e-05	0.000353	CcSEcCtD
Gliclazide—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	7.01e-05	0.000353	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL2—acquired immunodeficiency syndrome	7e-05	0.00908	CbGpPWpGaD
Gliclazide—Somnolence—Lamivudine—acquired immunodeficiency syndrome	7e-05	0.000352	CcSEcCtD
Gliclazide—Rash—Zidovudine—acquired immunodeficiency syndrome	6.95e-05	0.00035	CcSEcCtD
Gliclazide—Asthenia—Efavirenz—acquired immunodeficiency syndrome	6.95e-05	0.00035	CcSEcCtD
Gliclazide—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	6.94e-05	0.000349	CcSEcCtD
Gliclazide—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	6.93e-05	0.000349	CcSEcCtD
Gliclazide—Headache—Zidovudine—acquired immunodeficiency syndrome	6.91e-05	0.000347	CcSEcCtD
Gliclazide—Pruritus—Efavirenz—acquired immunodeficiency syndrome	6.85e-05	0.000345	CcSEcCtD
Gliclazide—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	6.83e-05	0.000344	CcSEcCtD
Gliclazide—Urticaria—Ritonavir—acquired immunodeficiency syndrome	6.81e-05	0.000343	CcSEcCtD
Gliclazide—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	6.8e-05	0.000342	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.79e-05	0.000342	CcSEcCtD
Gliclazide—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.78e-05	0.000341	CcSEcCtD
Gliclazide—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.78e-05	0.000341	CcSEcCtD
Gliclazide—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	6.77e-05	0.000341	CcSEcCtD
Gliclazide—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.77e-05	0.000341	CcSEcCtD
Gliclazide—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	6.74e-05	0.000339	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	6.74e-05	0.00874	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	6.73e-05	0.00873	CbGpPWpGaD
Gliclazide—Pain—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000339	CcSEcCtD
Gliclazide—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000339	CcSEcCtD
Gliclazide—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.65e-05	0.000335	CcSEcCtD
Gliclazide—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.63e-05	0.000333	CcSEcCtD
Gliclazide—Pruritus—Delavirdine—acquired immunodeficiency syndrome	6.56e-05	0.00033	CcSEcCtD
Gliclazide—Urticaria—Saquinavir—acquired immunodeficiency syndrome	6.55e-05	0.00033	CcSEcCtD
Gliclazide—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.55e-05	0.000329	CcSEcCtD
Gliclazide—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.52e-05	0.000328	CcSEcCtD
Gliclazide—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.52e-05	0.000328	CcSEcCtD
Gliclazide—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.52e-05	0.000328	CcSEcCtD
Gliclazide—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	6.48e-05	0.000326	CcSEcCtD
Gliclazide—Rash—Indinavir—acquired immunodeficiency syndrome	6.46e-05	0.000325	CcSEcCtD
Gliclazide—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.46e-05	0.000325	CcSEcCtD
Gliclazide—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.43e-05	0.000324	CcSEcCtD
Gliclazide—Headache—Indinavir—acquired immunodeficiency syndrome	6.42e-05	0.000323	CcSEcCtD
Gliclazide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.4e-05	0.000322	CcSEcCtD
Gliclazide—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.34e-05	0.000319	CcSEcCtD
Gliclazide—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.31e-05	0.000318	CcSEcCtD
Gliclazide—Urticaria—Lamivudine—acquired immunodeficiency syndrome	6.25e-05	0.000315	CcSEcCtD
Gliclazide—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.22e-05	0.000313	CcSEcCtD
Gliclazide—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.22e-05	0.000313	CcSEcCtD
Gliclazide—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.16e-05	0.00031	CcSEcCtD
Gliclazide—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.15e-05	0.000309	CcSEcCtD
Gliclazide—VEGFA—Differentiation Pathway—IL6—acquired immunodeficiency syndrome	6.13e-05	0.00795	CbGpPWpGaD
Gliclazide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.13e-05	0.000308	CcSEcCtD
Gliclazide—Rash—Efavirenz—acquired immunodeficiency syndrome	6.11e-05	0.000307	CcSEcCtD
Gliclazide—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.1e-05	0.000307	CcSEcCtD
Gliclazide—Nausea—Indinavir—acquired immunodeficiency syndrome	6.09e-05	0.000306	CcSEcCtD
Gliclazide—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.08e-05	0.000306	CcSEcCtD
Gliclazide—Headache—Efavirenz—acquired immunodeficiency syndrome	6.07e-05	0.000305	CcSEcCtD
Gliclazide—Pruritus—Ritonavir—acquired immunodeficiency syndrome	6.06e-05	0.000305	CcSEcCtD
Gliclazide—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.92e-05	0.000298	CcSEcCtD
Gliclazide—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.89e-05	0.000296	CcSEcCtD
Gliclazide—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.86e-05	0.000295	CcSEcCtD
Gliclazide—Rash—Delavirdine—acquired immunodeficiency syndrome	5.84e-05	0.000294	CcSEcCtD
Gliclazide—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.84e-05	0.000294	CcSEcCtD
Gliclazide—Pruritus—Saquinavir—acquired immunodeficiency syndrome	5.84e-05	0.000294	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	5.82e-05	0.00754	CbGpPWpGaD
Gliclazide—Headache—Delavirdine—acquired immunodeficiency syndrome	5.81e-05	0.000292	CcSEcCtD
Gliclazide—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	5.8e-05	0.000292	CcSEcCtD
Gliclazide—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.75e-05	0.000289	CcSEcCtD
Gliclazide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.67e-05	0.000285	CcSEcCtD
Gliclazide—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.65e-05	0.000284	CcSEcCtD
Gliclazide—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.64e-05	0.000284	CcSEcCtD
Gliclazide—Pruritus—Lamivudine—acquired immunodeficiency syndrome	5.57e-05	0.00028	CcSEcCtD
Gliclazide—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.5e-05	0.000277	CcSEcCtD
Gliclazide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.45e-05	0.000274	CcSEcCtD
Gliclazide—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.45e-05	0.000274	CcSEcCtD
Gliclazide—Rash—Ritonavir—acquired immunodeficiency syndrome	5.4e-05	0.000272	CcSEcCtD
Gliclazide—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.4e-05	0.000272	CcSEcCtD
Gliclazide—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.38e-05	0.000271	CcSEcCtD
Gliclazide—Headache—Ritonavir—acquired immunodeficiency syndrome	5.37e-05	0.00027	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	5.31e-05	0.00689	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL6—acquired immunodeficiency syndrome	5.27e-05	0.00683	CbGpPWpGaD
Gliclazide—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.24e-05	0.000264	CcSEcCtD
Gliclazide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.2e-05	0.000262	CcSEcCtD
Gliclazide—Rash—Saquinavir—acquired immunodeficiency syndrome	5.2e-05	0.000262	CcSEcCtD
Gliclazide—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.2e-05	0.000261	CcSEcCtD
Gliclazide—Headache—Saquinavir—acquired immunodeficiency syndrome	5.17e-05	0.00026	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—TNF—acquired immunodeficiency syndrome	5.1e-05	0.00661	CbGpPWpGaD
Gliclazide—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.09e-05	0.000256	CcSEcCtD
Gliclazide—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5e-05	0.000252	CcSEcCtD
Gliclazide—ABCC8—Metabolism—TAT—acquired immunodeficiency syndrome	4.97e-05	0.00645	CbGpPWpGaD
Gliclazide—Rash—Lamivudine—acquired immunodeficiency syndrome	4.96e-05	0.00025	CcSEcCtD
Gliclazide—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.96e-05	0.000249	CcSEcCtD
Gliclazide—Headache—Lamivudine—acquired immunodeficiency syndrome	4.93e-05	0.000248	CcSEcCtD
Gliclazide—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.9e-05	0.000247	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—TAT—acquired immunodeficiency syndrome	4.82e-05	0.00625	CbGpPWpGaD
Gliclazide—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.67e-05	0.000235	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.26e-05	0.00553	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AGPS—acquired immunodeficiency syndrome	4.23e-05	0.00548	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AGPS—acquired immunodeficiency syndrome	4.1e-05	0.00532	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	3.95e-05	0.00512	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IFNA1—acquired immunodeficiency syndrome	3.83e-05	0.00497	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	3.79e-05	0.00492	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	3.23e-05	0.00419	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	3.21e-05	0.00416	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.08e-05	0.00399	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.06e-05	0.00397	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	3.05e-05	0.00395	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—CSF2—acquired immunodeficiency syndrome	3e-05	0.00389	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.96e-05	0.00384	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	2.85e-05	0.0037	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.75e-05	0.00356	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.58e-05	0.00335	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.58e-05	0.00335	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	2.55e-05	0.00331	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	2.55e-05	0.00331	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.52e-05	0.00326	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.51e-05	0.00325	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.39e-05	0.0031	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.34e-05	0.00303	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.08e-05	0.00269	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.06e-05	0.00267	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.05e-05	0.00266	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ALB—acquired immunodeficiency syndrome	1.95e-05	0.00253	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.85e-05	0.0024	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.68e-05	0.00217	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.65e-05	0.00214	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.6e-05	0.00208	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.6e-05	0.00207	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—acquired immunodeficiency syndrome	1.59e-05	0.00206	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.57e-05	0.00203	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.44e-05	0.00187	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.44e-05	0.00187	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.36e-05	0.00177	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.00176	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.36e-05	0.00176	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.35e-05	0.00175	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.33e-05	0.00173	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—acquired immunodeficiency syndrome	1.33e-05	0.00173	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.31e-05	0.0017	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.22e-05	0.00159	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.18e-05	0.00153	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.12e-05	0.00145	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.09e-05	0.00141	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.00137	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.03e-05	0.00134	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.00132	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—acquired immunodeficiency syndrome	9.5e-06	0.00123	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.3e-06	0.00121	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—acquired immunodeficiency syndrome	8.67e-06	0.00112	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—acquired immunodeficiency syndrome	8.41e-06	0.00109	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.64e-06	0.000731	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	5.59e-06	0.000725	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.37e-06	0.000697	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.14e-06	0.000666	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.16e-06	0.00041	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	2.51e-06	0.000326	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.29e-06	0.000297	CbGpPWpGaD
